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Polymeric delivery systems based on nanoparticles have emerged as a promising approach for peroral insulin delivery. The aim
of the present study was to investigate the release of insulin nanoparticulate systems and ex vivo studies. The nanoparticles were
prepared by the ion gelation method. Particle size distribution, zeta potential, and polydispersity index of the nanoparticles were
determined.Itwasfoundthatthenanoparticlescarriedpositivechargesandshowedasizedistributionintherangeof170–200nm.
The electrostatic interactions between the positively charged group of chitosan and negatively charged groups of Arabic gum play
an important role in the association eﬃciency of insulin in nanoparticles. In vitro insulin release studies showed an initial burst
followed by a slow release of insulin. The mucoadhesion of the nanosystem was evaluated using excised rat jejunum. Ex vivo
studies have shown a signiﬁcant increase in absorption of insulin in the presence of chitosan nanoparticles in comparison with
free insulin.
1.Introduction
Since the parenteral administration is the only route of
insulin delivery, alternative routes of administration (oral,
nasal, rectal, pulmonary, and ocular) have been exten-
sively investigated [1]. Insulin is a protein composed of
two polypeptide chains which are covalently bound by
disulﬁde bonds between cysteine residues. Although peroral
application is considered as the most convenient route of
drug administration especially in long-term treatment, it
is well known that the bioavailability of insulin after oral
application is very low due to its instability in the gas-
trointestinal (GI) tract and its low permeability through
the intestinal mucosa, requiring nonoral routes of delivery
[2]. Moreover, oral administration of insulin would be
directly channeled from the intestine or colon to the liver to
avoid peripheral hyperinsulinemic eﬀects [3]. For successful
protein absorption from GI route, both the proteins and
peptides must overcome several barriers. Initially, they have
to overcome the destructive acidic pH in stomach. Secondly,
they have to be protected from the intensive proteolytic
enzymeactivityoftheintestine,and,ﬁnally,theyhavetopass
throughtheintestinalepithelialcellswhichpreventtransport
of macromolecules due to their structural properties [4].
Consequently, researchers have used diﬀerent strategies for
manufacturing tablets or developing drug carrier systems
capable of controlling drug delivery after oral administra-
tion.
Recent researches have determined that polymeric com-
pounds are useful carriers for high molecular weight drugs
[5]. Biodegradable polymers such as chitosan have been used
extensivelyinbiomedicalﬁeldsintheformofsutures,wound
covering and as artiﬁcial skin. Deacetylation of chitin, the
second most abundant biopolymer isolated from insects,
c r u s t a c e as u c ha sc r a ba n ds h r i m p s ,a sw e l la sf u n g i ,l e a d s
to poly(β-1,4-D-glucosamine) or so called chitosan [6].
Chitosan with excellent biocompatible and biodegradable
properties has been used extensively in the pharmaceutical2 ISRN Pharmaceutics
i n d u s t r ya sd r u gd e l i v e r ys y s t e m[ 7]. Moreover, chitosan has
been extensively investigated for its potential as a permeation
enhancer across intestinal epithelium for peptides and pro-
teins[8].Themucoadhesivepropertyofchitosanismediated
by its ability to spread over the mucus layer and additionally
its positive ionic interactions with the negative charges of the
cell surface membranes [9].
Arabicgum(Acacia),abiocompatibleandbiodegradable
polymer, is mainly used in oral and topical pharmaceutical
formulation as a suspending and emulsifying agent [10]. It is
alsousedinthepreparationoflozengesandasatabletbinder.
Arabic gum has also been evaluated as a bioadhesive in novel
tablet formulations and modiﬁed release tablets [10].
In the last decades, many strategies have been devel-
oped to enhance oral protein delivery [11]. Among these
approaches, nanoparticulate systems have attracted especial
interests for the following reasons. Firstly, nanoparticles are
abletoprotectactiveagentsfromdegradation[12].Secondly,
they can improve the drug transmucosal transport [13]a n d
transcytosis by M cells, and thirdly, the particulate systems
can provide controlled release properties for encapsulated
drugs [14]. In recent years, ion gelation or polyelectrolyte
complex formation (PEC) has drawn increasing attention
for producing nanoparticles containing peptides [15]. The
nanoparticles prepared by this method have several charac-
teristics favorable for cellular uptake and colloidal stability,
including suitable diameter and surface charge, spherical
morphology, and a low polydispersity index indicative of a
relatively homogeneous size distribution [16]. In addition,
this method has the advantage of not necessitating aggressive
conditions such as the presence of organic solvents and/or
sonication during preparation; therefore, minimizing pos-
sible damage to proteins and peptides during ion gelation
formation [17].
This study deals with in vitro insulin release and ex
vivo studies on intestinal section of sheep to investigate
the permeation of insulin in free form and in nanoparticle
form.
2. Experimental
2.1. Materials. Chitosan (95% deacetylated with viscosity of
1% W/V solution, 30mPa.s) was purchased from Primex
(Siglufjordur, Iceland). Crystalline recombinant human
insulin (28.3IU/mg) and Arabic gum were purchased from
Eli-Lilly (Suresnes, France) and Arthur Branwell (Braintree,
Essex,England),respectively.Theothermaterialsofpharma-
ceutical and analytical grades were used as received.
2.2. Preparation of Insulin Nanoparticles. The preparation of
insulin nanoparticles was performed by a method previously
set up in our laboratory [18]. Brieﬂy, Known amounts
of chitosan were dissolved in 0.1% of acetic acid solution
to obtain deﬁne concentration under stirring at room
temperature. In the second step, Arabic gum was dissolved
in water to obtain a known concentration under magnetic
stirring at room temperature. Nanoparticles were prepared
byaddingArabicgumsolutiondropwisetochitosansolution
Table 1: Parameters used in the factorial design experimental.
Factor Low level High level
(x1) Chitosan concentration (mg/mL) 1 10
(x2) Arabic gum concentration (mg/mL) 1 5
(x3) Insulin amount (mg) 5 10
Table 2: Three types of selected insulin nanoparticles based on
23 factorial design experiment. x1, x2,a n dx3 are chitosan con-
centration (mg/mL), Arabic gum concentration (mg/mL) and
insulin amount (mg) respectively, and association eﬃciency (run in
triplicate) was selected as the dependent variable (y).
Formulation code x1 x2 x3 y% (mean ± sd) (n = 3)
F1 10 1 5 31.2 ±2.83
F2 10 5 5 35.8 ±4.31
F3 1 051 0 3 7 .5 ±2.75
containing insulin under gentle magnetic stirring (200–
300rpm) at room temperature. Nanoparticles were recov-
eredbycentrifugationat4◦Cand14,000rpmfor15min,and
the supernatant was used for measurement of free Insulin
by HPLC chromatography (HPLC, youngling, SDV SOS,
Anyang, South Korea).
The best formulation was selected using a 23 factorial
design experiment (Table 2) and was further used for in vitro
r e l e a s es t u d i e sa sw e l la se xv i v op e r m e a t i o ns t u d i e s .
2.3. Characterization of Insulin Nanoparticles. Mean diam-
eter, polydispersity index (PDI), and Z-potential of insulin
nanoparticles were measured using zeta sizer apparatus
(Malvern, Z-S, Worcestershire, UK), and the range of poly-
dispersity index between 0-1 was determined. Nanoparticles
were analyzed with transmission electron microscopy (TEM,
Phillips 400, KW 80, Eindhoven, and Holland).
2.4. Insulin Association Eﬃciency. Brieﬂy, the insulin associa-
tion eﬃciency was measured by HPLC method. The amount
ofinsulinencapsulatedinthenanoparticleswascalculatedby
measuring the diﬀerence between the total amounts of the
insulin added in the nanoparticle preparation solution and
the amount of nonentrapped insulin remaining in the clear
supernatant after the centrifugation.
The insulin loading level in nanoparticles was calculated
based on the amount of insulin in the nanoparticles that was
determined by measuring insulin in the HCl medium after
ﬁltering through a 0.1μm syringe ﬁlter by HPLC method
[18].
2.5. In Vitro Release Study. Insulin release from nanopar-
ticles was done in three diﬀe r e n tp Hv a l u e so f0 . 1 NH C l ,
phosphate buﬀer solution (PBS) pH 6.5 and 7.2 in a 25mL
tube at 37◦C and 75rpm. Samples were withdrawn at
predetermined time intervals and ﬁltered through a 0.1μm
ﬁlter. The ﬁltrates were analyzed for the amount of insulin
using HPLC method.ISRN Pharmaceutics 3
Table 3: Characteristic of the nanoparticles containing insulin for diﬀerent formulations F1–F3.
Formulation code Mean diameter (nm, n = 3) Polydispersity Zeta potential (mv) AE (%) Loading capacity
F1 191 ±17 0.48 42.6 ±3.43 1 .2 ±2.83 11.8 ±0.56
F2 172 ±10 0.26 41.7 ±2.93 5 .8 ±4.31 13.73 ±0.43
F3 177 ±10 0.25 40.5 ±3.33 7 .5 ±2.75 16.28 ±0.78
O2-CO2
(i)
(j)
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
Mucosal ﬂuid (75mL)
Serosal ﬂuid (7.5mL)
Figure 1: Apparatus used in the ex vivo studies in intestine: (a) disposable syringe for collection of serosal ﬂuid, (b) hypodermic needle,
(c) rubber stopper, (d) conical ﬂask, (e) polyethylene centrifuge tube, (e) water bath (37◦C), (g) tape used to fasten intestine to tube, (h)
intestine, (i) mixture of gas inlet (O2 95% and CO2 5%), and (j) disposable plastic syringe used to collect mucosal ﬂuid.
2.6. Ex Vivo Study. The procedure used is a modiﬁcation of
Barr and Riegelman method with some adjustments [19]. At
ﬁrst a section of intestine (about 7cm) was removed from
a male sheep under Phenobarbital anesthesia and washed
with Krebs-Ringer bicarbonate solution, pH 7.4. The lumen
was inverted with a glass rod and a tube was inserted in
one side of the intestine and tied securely with tape. The
other side of the intestine was tied and 1mL of Krebs-Ringer
bicarbonate solution was poured through the hypodermic
needle in the tube. The lumen of intestine was placed in
a medium standard with 95% O2,5 %C O 2 in phosphate
buﬀer solution pH 6.5 at 37◦C. In absorption studies, O2
and CO2 mixture was bubbled into the intestinal to obtain
intestinal peristaltic movement (Figure 1). In certain periods
of time samples with known volume were collected from the
mediumandwereassayedbyHPLCmethod,andtheamount
of insulin was calculated.
3. Results andDiscussion
The insulin nanoparticles were prepared by ion gelation
method using the electrostatic interactions between pos-
itively charged chitosan and negatively charged Arabic
gum. In our previous study, various formulations (F1–F8)
were prepared using 23 factorial design experiments [18].
According to the results of factorial design experiments,
three formulations (Table 2) were selected. The association
eﬃciency (AE) of the nanoparticles was investigated in this
study.
Moreover, the electrostatic interactions between the
positively charged group of chitosan and negatively charged
Table 4: Kinetic constants (k), diﬀusional (n) and determination
coeﬃcient (r2) determined by the linear regression of Ln(Mt/M∞)
against Lnt.
Formulation n (X ±SD, n = 3) k (X ±SD, n = 3) r2
F2 0.823 ±0.0341 0.0008 ±0.0001 0.956
F3 0.494 ±0.0268 0.0019 ±0.0003 0.958
groups of Arabic gum plays an important role in the
association eﬃciency of insulin in nanoparticles. These
studies have shown that increasing the concentrations of
chitosan and Arabic gum or the amount of insulin used
in nanoparticle preparation are important factors in AE
(Table 2)[ 18]. Figure 2 shows the TEM photograph of the
nanoparticles. The nanoparticles showed spherical or oval
shapes with relatively smooth surface. According to these
ﬁgures and the results obtained from the zeta potential
studies, the positive charges on the surface of nanoparticles
could prevent the aggregation process.
The particle size of nanoparticles is presented in Table 3
for the three selected formulations. The mean diameter of
particles is 191, 172, and 177 nanometers for formulations
F1,F 2,a n dF 3, respectively, and exhibited relatively narrow
particle size distribution, as indicated by a relatively low
polydispersity index values (Table 3). Zeta potential is
used to determine the surface charge of nanoparticles [20].
Chitosan nanoparticles are all positively charged as shown
in Table 3. This could be related to the type of particle
formation mechanism between positively charged amine
groups of chitosan that are neutralized by their interaction
with negative charge of Arabic gum polymer. The residual4 ISRN Pharmaceutics
(a) (b)
Figure 2: TEM micrographs of insulin nanoparticles for formulation (a) F2 and (b) F3.
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Figure 3: In vitro release proﬁle of insulin from chitosan nanopar-
ticles in HCl, pH 1.2.
amine groups would be responsible for the positive zeta
potential. This eﬀect may be related to the absorption of
anionic groups by the long amino groups of chitosan to keep
the high value of the electrical double layer thickness which
in turn prevents the aggregation [21].
The insulin release of nanoparticles was studied as a
function of time for formulation F3. Figures 3 and 4 have
shown the release proﬁle of insulin in three diﬀerent pH
medium HCl 0.1N, PBS pH 6.5, and pH 7.2 [18]. A
burst eﬀect of insulin release in acidic medium is related
to high solubility of both chitosan and insulin (Figure 3).
Furthermore, it is fair to say that a lot of insulin molecules
are loosely attached on the surface of nanoparticles, and
therefore insulin tends to easily move out and diﬀuse to the
external medium.
As shown in Figure 4 the release proﬁle of insulin from
the nanoparticles is diﬀerent in higher pH values of 6.5 and
7.2. Moreover, the solubility of chitosan and insulin in PBS is
lower than acidic medium and therefore a burst eﬀect was
not observed. The diﬀerence in insulin release at PBS pH
6.5 and 7.2 is probably related to the presence of Arabic
gum. Arabic gum has a pH value of 4.5–5.0 in 5% W/V
aqueoussolutionandthereforethepolymerchainsmayswell
in pH mediums higher than 6.5 and obtain more porosity
in nanoparticle structures, resulting in more insulin release.
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Figure 4: In vitro release proﬁles of insulin from chitosan nanopar-
ticles in phosphate buﬀer solution, pH 6.5 and pH 7.2.
Formorestudies,FickianandnonFickianbehaviorhavebeen
used for determining the mechanism of drug release.
Equation Mt/M∞ = ktn was used, where Mt is the
amount of released insulin in a given time, M∞ is the total
amount of insulin within nanoparticles, k and n are the
equation constants, and t is the time. Table 4 has shown the
result for kinetic constant, diﬀusional constant, and type of
release mechanism in formulation F2 and F3. The value of
0.823 for formulation F2 and 0.494 for formulation F3 are
related to nonFickian transport [18]. The result suggests that
transport is possibly controlled by diﬀusion and/or swelling
of the polymer chains.
Today, the uptake of nanoparticulate systems through
the gastrointestinal tract is a well-known and accepted
phenomenon, and excellent reviews of the intestinal uptake
of particles have been published. The bioactive moleculesISRN Pharmaceutics 5
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Figure 5: A simpliﬁed schematic of preabsorption and postabsorption processes in nanoparticle-dependent drug delivery to gastrointestinal
sited following oral administration, highlighting the variety of processes involved in the journey of a nanoparticle from delivery to target.
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Figure 6: Proﬁle of the amount of insulin absorption as function
time for F1 (), F2 (), and F3 () nanoparticle formulations as
well and as free insulin ().
are transported into the GI by carriers with speciﬁc physic-
ochemical characteristics that have no eﬀect on the drug.
Figure5showsthesimpliﬁedschematicofpreabsorptionand
postabsorption processes in nanoparticle dependent drug
delivery to gastrointestinal sites following oral administra-
tion.
The amount of insulin transported across the intestine
barrier was measured by using modiﬁed gut sac method.
Permeation proﬁles of insulin from formulation F1,F 2 F3
as well as free insulin samples are depicted in Figure 6.I t
is clearly demonstrated that the permeation of insulin in
the serosal medium in nanoparticulate form is much more
enhancedincomparisonwithfree-solubleinsulin.Moreover,
insulin is a macromolecule with hydrophilic properties that
is not easily transported across the cellular membrane.
Nanoparticulatesystemsfacilitatethetransportofinsulin
through the intestinal barrier due to their protective eﬀect
as well as their charge properties. For the nanoparticles to
be able to be permeated via the gut-associated lymphoid
tissues the physical characteristic of the nanoparticles such
as size, shape, speciﬁc surface, surface charge, and chemical
stability are important factors to be considered. Moreover,
the potential interactions with gut contents, transit time
through the GI, transport through the mucosa, adhesion
to epithelial surfaces, and aggregation of the particulates in
contact with the ﬂuid content of the gut must be considered.
Some phenomena, such as aggregation, adsorption, and
adhesion, can alter the zeta potential, hydrophilicity, and size
of the nanoparticles. The zeta potential and mean diameter
for F1,F 2,a n dF 3 formulations are close to each other so
we cannot show the signiﬁcant diﬀerence between these
formulations (P<0.05). In the intracellular pathway, it
seems that nanoparticles regardless of their particle size are
able to move through the cellular membrane via transcytosis
or endocytosis mechanisms.
In intercellular pathway, the presence of tight junction
between adjacent epithelial cells is the main barrier to the
passage of macromolecules and hydrophilic agents such as
peptides and proteins. The presence of the positive charge on
the surface of the nanoparticles may interact with the actin
ﬁlaments of intestinal epithelium disrupting the structure of
the tight junctions and enabling the permeability of insulin
through these junctions.
4. Conclusions
The main goal of administration of nanoparticles by the oral
route is to lower the dose of the drug (and consequently to
diminish its toxicity) as well as to improve patient compli-
ance and supply an easy administration route. Other aims
may be to decrease the fed/fasted variability and patient-
to-patient variability. Eﬃcient incorporation of bioactive
molecules in nanoparticles requires in-depth study.
Hydrophilic nanoparticles based on chitosan are receiv-
ing increased interest as they could control the rate of drug6 ISRN Pharmaceutics
release, prolong the duration of the therapeutic eﬀect, and
deliver the drug to speciﬁc sites in the body.
In this study, we developed a new nanoparticle system
with Arabic gum for oral delivery of insulin. The eﬀect of
diﬀerent variables on nanoparticle preparation was investi-
gated.Resultshaveindicatedasmallsize,positivecharge,and
median AE for nanoparticles. It was shown that the release of
insulin from nanoparticles was obtained with more than one
mechanism(possiblydiﬀusion,dissolution,andrelaxationof
the polymer chains).
Results showed that chitosan nanoparticles are able
to enhance permeation of insulin as hydrophilic models
through intestine epithelium. Indeed, our preliminary stud-
ies have shown that all the nanoparticles formulations
are able to increase the amount of insulin transported
across the intestine barrier compared to free insulin sample.
Understanding the structure and function of bilayer of cell
membrane and proteins that are involved in the formation
of the intercellular junctions may create a new ﬁeld for
developing diﬀerent mechanisms of drug permeation. Fur-
ther investigations are required and are in progress in our
laboratory to fully characterize and optimize these systems.
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